You are here

Science

Ebola Transmission Through Cough Possible, But Not Likely: Experts

HEALTHDAY NEWS   by Dennis Thompson                                                                 Feb. 19, 2015

The cough of very sick Ebola patients could be as dangerous as their vomit or diarrhea to those around them, a new report suggests.

However, the same experts also cautioned that this does not mean that the deadly virus could spread quickly through the air, as illnesses like measles or flu do.

The report "shouldn't be something that alarms the public into believing that Ebola could become airborne in the way that measles is," said Dr. Amesh Adalja, a senior associate at the University of Pittsburgh Medical Center's Center for Health Security.

"This paper doesn't say that," said Adalja, who was not involved in the study.

Read complete story:
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

CDC Ready to Vaccinate 6,000 Against Ebola in Sierra Leone

NBC NEWS by Maggie Fox                                                                             Feb. 19, 2015

The Centers for Disease Control and Prevention is helping prepare for a new Ebola vaccine trial in Sierra Leone, the country that's now the worst hit by the Ebola epidemic.

The CDC will work with Sierra Leonean authorities to vaccinate up to 6,000 health care workers, including doctors, nurses and ambulance drivers, against a virus that's infected more than 11,000 people in Sierra Leone alone, killing 3,400 of them.

This trial will test just one of the Ebola vaccines in development - one designed by U.S. and Canadian government researchers with a company called New Link Genetics and licensed to Merck. It uses an animal virus called vesicular stomatitis virus (VSV) to carry tiny pieces of the Ebola virus to help train the immune system to recognize it.

Read complete story.
http://www.nbcnews.com/storyline/ebola-virus-outbreak/cdc-ready-vaccinate-6-000-against-ebola-sierra-leone-n308576

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

How to Detect Infectious Diseases Like Ebola Faster

New tools aim to deliver quicker test results—and prevent disease from spreading


(Two stories, scroll down.)

 WALL STREET JOURNAL by Betsy Mckay                           Feb. 17, 2015

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola virus evolution tracked by genetic data

SCIENCE NEWS by Ashley Yaeger                               Feb. 14, 2015
SAN JOSE, Calif. — Genetic data are beginning to reveal how the Ebola virus causing the epidemic in Western Africa is evolving.

            LITTLE TWEAKS  A detailed look at genomes of the Ebola virus has pinpointed mutations that may make one type  of experimental therapy less effective. Cynthia Goldsmith/CDC

Scientists have deciphered the entire catalog of genetic data for 96 Ebola viruses taken from patients infected in 2014 during the first four months of the outbreak.

The results show that one particular clade, or type of the virus, is dominant among patients in Sierra Leone, suggesting that two other clades that dominated early on in the outbreak have died out.

This third clade appears to have evolved starting with a single mutation in the genetic catalog, or genome, of the virus, said Stephen Gire of Harvard University and the Broad Institute in Cambridge, Mass. He presented the preliminary findings February 14 at the annual meeting of the American Association for the Advancement of Science.

Read full article.

Problem, Solution, SitRep, or ?: 

Use of Group Quarantine in Ebola Control — Nigeria, 2014

Morbidity and Mortality Weekly Report (MMWR)

CDC                                                                                                                            Feb. 13, 2015

by Cheri Grigg, DVM1,2, Ndadilnasiya E. Waziri, DVM3, Adebola T. Olayinka, MD3, John F. Vertefeuille, PhD4

On July 20, 2014, the first known case of Ebola virus disease (Ebola) in Nigeria, in a traveler from Liberia  led to an outbreak that was successfully curtailed with infection control, contact tracing, isolation, and quarantine measures coordinated through an incident management system.

During this outbreak, most contacts underwent home monitoring, which included instructions to stay home or to avoid crowded areas if staying home was not possible. However, for five contacts with high-risk exposures, group quarantine in an observation unit was preferred because the five had crowded home environments or occupations that could have resulted in a large number of community exposures if they developed Ebola.

Read complete report.

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6405a3.htm?s_cid=mm6405a3_x

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Doctors Who Treat Ebola Feel More Socially Isolated

LIVESCIENCE.COM   by Rachael Rettner                                                                         Feb. 13, 2015

Doctors who take care of very sick Ebola patients may feel socially isolated, but surprisingly, they may not feel more stressed than usual, a new study from Germany suggests.

Researchers surveyed 46 health care workers who treated Germany's first Ebola patient in August 2014, as well as 40 health care workers who worked in the same hospital but did not treat the Ebola patient.

The researchers who did the study hypothesized that the people who treated the Ebola patient would have more symptoms of psychological distress because they were working in a challenging environment that presented a risk that they could become infected with the deadly virus.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Lack of Effect of Lamivudine on Ebola Virus Replication

CDC EID JOURNAL by  Lisa E. Hensley, Julie Dyall, Gene G. Olinger, and Peter B. Jahrlin (NIH)                     Feb. 12, 2015

The unprecedented number of Ebola virus disease (EVD) cases in western Africa has compelled the world to consider experimental and off-label therapeutics to mitigate the current outbreak. For clinicians, approved drugs are an attractive solution because of known safety profiles and availability.

Oral lamivudine (GlaxoSmithKline, Brentford, UK), a US Food and Drug Administration–approved anti-HIV drug, has been suggested as a possible antiviral agent against Ebola virus (EBOV). In September 2014, a Liberian physician, Dr. Gorbee Logan, reported positive results while treating EVD with lamivudine (1). Thirteen of 15 patients treated with lamivudine survived presumed EVD and were declared virus free. Clinical confirmation of EVD in these cases remains to be verified....

Problem, Solution, SitRep, or ?: 

Postmortem Stability of Ebola Virus

CDC  EID JOURNAL                                              Feb. 12, 2015                                   
Study by Joseph Prescott, Trenton Bushmaker, Robert Fischer, Kerri Miazgowicz, Seth Judson, and Vincent J. Munster

The ongoing Ebola virus outbreak in West Africa has highlighted questions regarding stability of the virus and detection of RNA from corpses. We used Ebola virus–infected macaques to model humans who died of Ebola virus disease.

Assessing the stability of corpse-associated virus and determining the most efficient sampling methods for diagnostics will clarify the safest practices for handling bodies and the best methods for determining whether a person has died of EVD and presents a risk for transmission. To facilitate diagnostic efforts, we studied nonhuman primates who died of EVD to examine stability of the virus within tissues and on body surfaces to determine the potential for transmission, and the presence of viral RNA associated with corpses.

http://wwwnc.cdc.gov/eid/article/21/5/15-0041_article

Problem, Solution, SitRep, or ?: 

Ebola: Call for more sharing of scientific data

BBC NEWS      by Helen Briggs, Environment correspondent                                                                     Feb. 2, 2015

The devastation left by the Ebola virus in west Africa raises many questions for science, policy and international development.

One issue that has yet to receive widespread media attention is the handling of genetic data on the virus.

By studying its code, scientists can trace how Ebola leapt across borders, and how, like all viruses, it is constantly evolving and changing.

Yet, researchers have been privately complaining for months about the scarcity of genetic information about the virus that is entering the public domain.

In the last few days, scientists have been speaking on and off the record about their concerns.

http://www.bbc.com/news/science-environment-31091816

Problem, Solution, SitRep, or ?: 

Health Ebola Vaccines Trial Starts in Liberia

ASSOCIATED PRESS by JONATHAN PAYE-LAYLEH                                                        Feb. 2, 2015

MONROVIA--A large-scale human trial of two potential Ebola vaccines got under way in Liberia's capital Monday, part of a global effort to prevent a repeat of the epidemic that has now claimed nearly 9,000 lives in West Africa.

The trials in Liberia are taking place after smaller studies determined that the vaccines were safe for human use. By comparing them now with a placebo shot, scientists hope to learn whether they can prevent people from contracting the ghastly virus that has killed some 60 percent of those hospitalized with the disease.

Yet despite the trials' promise, authorities still must combat fear and suspicion that people could become infected by taking part. Each vaccine uses a different virus to carry non-infectious Ebola genetic material into the body and spark an immune response.

Read complete story.
http://abcnews.go.com/Health/wireStory/ebola-vaccine-trial-starts-liberia-28657084

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Science
howdy folks